Journal Mobile Options
Table of Contents
Vol. 88, No. 1, 2010
Issue release date: January 2010
Stereotact Funct Neurosurg 2010;88:51–55

Pedunculopontine Nucleus Deep Brain Stimulation in a Patient with Primary Progressive Freezing Gait Disorder

Ostrem J.L. · Christine C.W. · Glass G.A. · Schrock L.E. · Starr P.A.
Departments of aNeurology and bNeurosurgery, University of California San Francisco, Center for the Surgical Treatment of Movement Disorders, San Francisco, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Pedunculopontine nucleus (PPN) deep brain stimulation (DBS) has recently been suggested for treatment of medication-unresponsive gait and axial symptoms in Parkinson’s disease. Patients with the rare primary progressive freezing gait disorder (PPFG) have similar disabling symptoms and few therapeutic options. We report here on our experience with PPN DBS in treating a 76-year-old man with medication-refractory PPFG. Methods: The patient was treated with staged PPN DBS and underwent careful pre- and postoperative clinical evaluations up to 12 months after surgery. Results: PPN DBS resulted in only mild improvement in symptoms after 12 months of stimulation. Conclusion: In this single case of a patient with PPFG, PPN DBS served only a limited role in treating his symptoms and adds to the very limited published literature describing patients treated with DBS at this brain target.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Munro-Davies LE, Winter J, Aziz TZ, Stein JF: The role of the pedunculopontine region in basal-ganglia mechanisms of akinesia. Exp Brain Res 1999;129:511–517.
  2. Nandi D, Liu X, Winter JL, Aziz TZ, Stein JF: Deep brain stimulation of the pedunculopontine region in the normal non-human primate. J Clin Neurosci 2002;9:170–174.
  3. Nandi D, Aziz TZ, Giladi N, Winter J, Stein JF: Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain 2002;125:2418–2430.
  4. Jenkinson N, Nandi D, Miall RC, Stein JF, Aziz TZ: Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 2004;15:2621–2624.
  5. Mazzone P, Lozano A, Stanzione P, Galati S, Scarnati E, Peppe A, et al: Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson’s disease. Neuroreport 2005;16:1877–1881.
  6. Plaha P, Gill SS: Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. Neuroreport 2005;16:1883–1887.
  7. Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, et al: Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 2007;130:1596–1607.
  8. Zrinzo L, Zrinzo LV, Hariz M: The pedunculopontine and peripeduncular nuclei: a tale of two structures. Brain 2007;130:e73; author reply e74.
  9. Factor SA, Jennings DL, Molho ES, Marek KL: The natural history of the syndrome of primary progressive freezing gait. Arch Neurol 2002;59:1778–1783.
  10. Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD: Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord 2000;6:165–170.
  11. Shimamoto S, Larson PS, Sani SB, Ostrem JL, Glass GA, Turner RS, et al: Single Unit Discharge in the Human Pedunculopontine Nucleus. Vancouver, American Society for Stereotactic and Functional Neurosurgery, 2008.
  12. Zrinzo L, Zrinzo LV, Tisch S, Limousin PD, Yousry TA, Afshar F, et al: Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. Brain 2008;131:1588–1598.
  13. Factor SA, Higgins DS, Qian J: Primary progressive freezing gait: a syndrome with many causes. Neurology 2006;66:411–414.
  14. Compta Y, Valldeoriola F, Tolosa E, Rey MJ, Marti MJ, Valls-Sole J: Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord 2007;22:1954–1958.
  15. Factor SA: The clinical spectrum of freezing of gait in atypical parkinsonism. Mov Disord 2008;23(suppl 2):S431–S438.
  16. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.
  17. Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, et al: Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord 2009;24:655–661.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50